CNTB Stock Forecast & Price Target

Connect Biopharma Hldgs is supported by rademikibart’s clear clinical differentiation in acute respiratory disease, highlighted by an 81% reduction in COPD treatment failure, 85% fewer new moderate-to-severe exacerbations, and 100% fewer hospital/ED returns versus placebo. The favorable safety profile, rapid symptom improvement, and significant rescue-inhaler reduction strengthen the case that the drug can address outcomes patients, physicians, and payers value most, while the roughly $70M market capitalization suggests the market may be underappreciating the opportunity. In addition, the same data create a credible bridge from acute exacerbation care into chronic COPD and reinforce the broader asthma program ahead of 4Q26 FDA alignment and other upcoming catalysts.

Connect Biopharma Hldgs is a clinical-stage biopharmaceutical company whose bearish case rests on execution and financing risk around rademikibart, because the stock depends on unproven acute asthma and COPD data rather than commercial revenue. The company’s model already assumes a 14.1% weighted average cost of capital and a 14.0x exit multiple on 2036 estimates, while explicit risks include development, financing, competitive, regulatory, geopolitical, and delisting risk. The upcoming STAT COPD readout is viewed with caution because blinded event rates still trail ABRA and remain well below the ~45% 30-day benchmark used for powering, raising the risk of another treatment-failure miss and a potential cash overhang.